Turnstone Biologics Corp.
Stock Forecast, Prediction & Price Target

	Passed			Analyst forecast
Metric	12/31/2021	12/31/2022	12/31/2023	12/31/2025	12/31/2026
Revenue % change YoY	$101.29M N/A	$73.3M -27.63%	$19.30M -73.66%	Avg: $4.70M Low: $4.70M High: $4.70M avg. -75.64%	Avg: $2.32M Low: $2.32M High: $2.32M avg. -50.64%
Net Income % change YoY	$33.26M N/A	$-30.83M -192.68%	$-55.2M -79.02%	Avg: $-99.33M Low: $-45.32M High: $-27.40M avg. -79.96%	Avg: $-112.55M Low: $-34.80M High: $-34.57M avg. -13.29%
EBITDA % change YoY	$34.38M N/A	$-27.72M -180.63%	$-56.23M -102.82%	Avg: $-1.62M Low: $-1.62M High: $-1.62M avg. 97.10%	Avg: $-803.52K Low: $-803.52K High: $-803.52K avg. 50.64%
EPS % change YoY	$1.5 N/A	-$1.39 -192.66%	-$4.77 -243.16%	Avg: -$3.01 Low: -$3.92 High: -$2.37 avg. 36.89%	Avg: -$3 Low: -$3.01 High: -$2.99 avg. 0.33%
Operating Expenses % change YoY	$68.3M N/A	$104.92M 53.62%	$78.33M -25.33%	Avg: $2.04M Low: $2.04M High: $2.04M avg. -97.38%	Avg: $1.01M Low: $1.01M High: $1.01M avg. -50.64%

FAQ

Wall Street analysts estimate the annual average earnings growth rate of -46.63% in 2025-2026.

We have gathered data from 2 analysts. Their low estimate is -45.32M, average is -99.33M and high is -27.40M.

Wall Street analysts forecast annual average revenue growth of -63.14% in 2025-2026.

We have gathered data from 2 analysts. Their low revenue estimate is $4.70M, average is $4.70M and high is $4.70M.

Wall Street analysts forecast annual average earnings growth of 18.61% in 2025-2026.

We have gathered data from 2 analysts. Their low earnings per share estimate is -$3.92, average is -$3.01 and high is $-2.37.

In the last twelve months analysts have been covering Turnstone Biologics Corp. stock. The most successful analyst is Charlie Yang.